Arch Therapeutics, Inc. provided a commercialization update on the Company's first product, AC5 Advanced Wound System. Since the Centers for Medicare and Medicaid Services established A2020, a Level II Healthcare Common Procedure Coding System code dedicated to AC5, both orders and payments for submitted claims have accelerated. Since the April 1, 2023 effective date of A2020, average monthly order volume for AC5 has grown significantly, increasing over four-fold when compared to average monthly order volume from the first calendar quarter.

At any given time, there are more than 7 million challenging wounds in the U.S., with approximately 4 million new wounds emerging each year. AC5 is cleared by the Food and Drug Administration for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing.